FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1830102405> ?p ?o ?g. }

• W1830102405 endingPage "884" @default.
• W1830102405 startingPage "884" @default.
• W1830102405 abstract "Importance Steroidal mineralocorticoid receptor antagonists, when added to a renin-angiotensin system blocker, further reduce proteinuria in patients with chronic kidney disease but may be underused because of a high risk of adverse events. Objective To evaluate the safety and efficacy of different oral doses of the nonsteroidal mineralocorticoid receptor antagonist finerenone, given for 90 days to patients with diabetes and high or very high albuminuria who are receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. Design, Setting, and Participants Randomized, double-blind, placebo-controlled, parallel-group study conducted at 148 sites in 23 countries. Patients were recruited from June 2013 to February 2014 and the study was completed in August 2014. Of 1501 screened patients, 823 were randomized and 821 received study drug. Interventions Participants were randomly assigned to receive oral, once-daily finerenone (1.25 mg/d, n = 96; 2.5 mg/d, n = 92; 5 mg/d, n = 100; 7.5 mg/d, n = 97; 10 mg/d, n = 98; 15 mg/d, n = 125; and 25 mg/d, n = 119) or matching placebo (n = 94) for 90 days. Main Outcomes and Measures The primary outcome was the ratio of the urinary albumin-creatinine ratio (UACR) at day 90 vs at baseline. Safety end points were changes from baseline in serum potassium and estimated glomerular filtration rate. Results The mean age of the participants was 64.2 years; 78% were male. At baseline, 36.7% of patients treated had very high albuminuria (UACR ≥300 mg/g) and 40.0% had an estimated glomerular filtration rate of 60 mL/min/1.73 m 2 or lower. Finerenone demonstrated a dose-dependent reduction in UACR. The primary outcome, the placebo-corrected mean ratio of the UACR at day 90 relative to baseline, was reduced in the finerenone 7.5-, 10-, 15-, and 20-mg/d groups (for 7.5 mg/d, 0.79 [90% CI, 0.68-0.91; P  = .004]; for 10 mg/d, 0.76 [90% CI, 0.65-0.88; P  = .001]; for 15 mg/d, 0.67 [90% CI, 0.58-0.77; P P Conclusions and Relevance Among patients with diabetic nephropathy, most receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, the addition of finerenone compared with placebo resulted in improvement in the urinary albumin-creatinine ratio. Further trials are needed to compare finerenone with other active medications. Trial Registration clinicaltrials.gov Identifier:NCT1874431" @default.
• W1830102405 created "2016-06-24" @default.
• W1830102405 creator A5000418035 @default.
• W1830102405 creator A5005549802 @default.
• W1830102405 creator A5007174365 @default.
• W1830102405 creator A5012514694 @default.
• W1830102405 creator A5019931026 @default.
• W1830102405 creator A5023556434 @default.
• W1830102405 creator A5049235067 @default.
• W1830102405 creator A5050612283 @default.
• W1830102405 creator A5062670268 @default.
• W1830102405 creator A5067220785 @default.
• W1830102405 creator A5074496684 @default.
• W1830102405 creator A5078153195 @default.
• W1830102405 creator A5085592050 @default.
• W1830102405 creator A5089305017 @default.
• W1830102405 creator A5091832416 @default.
• W1830102405 date "2015-09-01" @default.
• W1830102405 modified "2023-10-11" @default.
• W1830102405 title "Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy" @default.
• W1830102405 cites W1987852307 @default.
• W1830102405 cites W2000812251 @default.
• W1830102405 cites W2019223575 @default.
• W1830102405 cites W2072070798 @default.
• W1830102405 cites W2072124509 @default.
• W1830102405 cites W2072577267 @default.
• W1830102405 cites W2079169053 @default.
• W1830102405 cites W2088495121 @default.
• W1830102405 cites W2088988299 @default.
• W1830102405 cites W2090526184 @default.
• W1830102405 cites W2091788165 @default.
• W1830102405 cites W2096875294 @default.
• W1830102405 cites W2116077357 @default.
• W1830102405 cites W2116687798 @default.
• W1830102405 cites W2118932957 @default.
• W1830102405 cites W2119248404 @default.
• W1830102405 cites W2125089162 @default.
• W1830102405 cites W2130827265 @default.
• W1830102405 cites W2132715232 @default.
• W1830102405 cites W2138612646 @default.
• W1830102405 cites W2138862624 @default.
• W1830102405 cites W2141386688 @default.
• W1830102405 cites W2162368776 @default.
• W1830102405 cites W2297164013 @default.
• W1830102405 cites W1901408770 @default.
• W1830102405 doi "https://doi.org/10.1001/jama.2015.10081" @default.
• W1830102405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26325557" @default.
• W1830102405 hasPublicationYear "2015" @default.
• W1830102405 type Work @default.
• W1830102405 sameAs 1830102405 @default.
• W1830102405 citedByCount "485" @default.
• W1830102405 countsByYear W18301024052015 @default.
• W1830102405 countsByYear W18301024052016 @default.
• W1830102405 countsByYear W18301024052017 @default.
• W1830102405 countsByYear W18301024052018 @default.
• W1830102405 countsByYear W18301024052019 @default.
• W1830102405 countsByYear W18301024052020 @default.
• W1830102405 countsByYear W18301024052021 @default.
• W1830102405 countsByYear W18301024052022 @default.
• W1830102405 countsByYear W18301024052023 @default.
• W1830102405 crossrefType "journal-article" @default.
• W1830102405 hasAuthorship W1830102405A5000418035 @default.
• W1830102405 hasAuthorship W1830102405A5005549802 @default.
• W1830102405 hasAuthorship W1830102405A5007174365 @default.
• W1830102405 hasAuthorship W1830102405A5012514694 @default.
• W1830102405 hasAuthorship W1830102405A5019931026 @default.
• W1830102405 hasAuthorship W1830102405A5023556434 @default.
• W1830102405 hasAuthorship W1830102405A5049235067 @default.
• W1830102405 hasAuthorship W1830102405A5050612283 @default.
• W1830102405 hasAuthorship W1830102405A5062670268 @default.
• W1830102405 hasAuthorship W1830102405A5067220785 @default.
• W1830102405 hasAuthorship W1830102405A5074496684 @default.
• W1830102405 hasAuthorship W1830102405A5078153195 @default.
• W1830102405 hasAuthorship W1830102405A5085592050 @default.
• W1830102405 hasAuthorship W1830102405A5089305017 @default.
• W1830102405 hasAuthorship W1830102405A5091832416 @default.
• W1830102405 hasBestOaLocation W18301024052 @default.
• W1830102405 hasConcept C126322002 @default.
• W1830102405 hasConcept C126894567 @default.
• W1830102405 hasConcept C134018914 @default.
• W1830102405 hasConcept C17744445 @default.
• W1830102405 hasConcept C199539241 @default.
• W1830102405 hasConcept C2776174234 @default.
• W1830102405 hasConcept C2779473830 @default.
• W1830102405 hasConcept C2779922275 @default.
• W1830102405 hasConcept C2781184683 @default.
• W1830102405 hasConcept C555293320 @default.
• W1830102405 hasConcept C71924100 @default.
• W1830102405 hasConceptScore W1830102405C126322002 @default.
• W1830102405 hasConceptScore W1830102405C126894567 @default.
• W1830102405 hasConceptScore W1830102405C134018914 @default.
• W1830102405 hasConceptScore W1830102405C17744445 @default.
• W1830102405 hasConceptScore W1830102405C199539241 @default.
• W1830102405 hasConceptScore W1830102405C2776174234 @default.
• W1830102405 hasConceptScore W1830102405C2779473830 @default.
• W1830102405 hasConceptScore W1830102405C2779922275 @default.
• W1830102405 hasConceptScore W1830102405C2781184683 @default.
• W1830102405 hasConceptScore W1830102405C555293320 @default.

• next